Ironwood Pharmaceuticals Stock Forecast, Price & News

-0.27 (-2.03 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.44 million shs
Average Volume2.00 million shs
Market Capitalization$2.11 billion
P/E Ratio14.61
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ironwood Pharmaceuticals logo

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.88 out of 5 stars

Medical Sector

685th out of 1,309 stocks

Pharmaceutical Preparations Industry

343rd out of 646 stocks

Analyst Opinion: 1.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

Is Ironwood Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ironwood Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRWD, but not buy additional shares or sell existing shares.
View analyst ratings for Ironwood Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ironwood Pharmaceuticals?

Wall Street analysts have given Ironwood Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ironwood Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Ironwood Pharmaceuticals

How can I listen to Ironwood Pharmaceuticals' earnings call?

Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-621-4642 with passcode "2598317".

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The biotechnology company earned $88.80 million during the quarter, compared to analyst estimates of $87.94 million. Ironwood Pharmaceuticals had a net margin of 35.83% and a trailing twelve-month return on equity of 447.47%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.04 EPS.
View Ironwood Pharmaceuticals' earnings history

How has Ironwood Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IRWD stock has increased by 23.8% and is now trading at $13.00.
View which stocks have been most impacted by COVID-19

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $370 million-$385 million, compared to the consensus revenue estimate of $394.42 million.

What price target have analysts set for IRWD?

4 brokerages have issued 1-year price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Ironwood Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:
  • Ms. Julie H. McHugh, Exec. Chairman (Age 57, Pay $95k)
  • Mr. Thomas A. McCourt, CEO & Director (Age 64, Pay $944.57k)
  • Ms. Gina R. Consylman CPA, Principal Accounting Officer, CFO, Sr. VP & Treasurer (Age 48, Pay $788.44k)
  • Mr. Jason Rickard, COO & Sr. VP of Operations (Age 50, Pay $940.06k)
  • Dr. Michael Shetzline M.D., Ph.D., Chief Medical Officer, Sr. VP & Head of Drug Devel. (Age 62, Pay $770.28k)
  • Mr. Brian M. Cali, Co-Founder and Sr. VP of R&D Strategy & External Innovation
  • Mr. G. Todd Milne, Co-Founder and VP of sGC R&D
  • Ms. Meredith Kaya, VP of Investor Relations & Corp. Communications
  • Brian S. Tessler, Sec. & Interim Gen. Counsel
  • Mr. Jonathan Rosin, Sr. VP of HR

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (1.46%), Alliancebernstein L.P. (0.15%), Fisher Asset Management LLC (0.06%), Jackson Creek Investment Advisors LLC (0.06%), Victory Capital Management Inc. (0.03%) and Arizona State Retirement System (0.03%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Gina Consylman, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and Arizona State Retirement System. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Jackson Creek Investment Advisors LLC, Fisher Asset Management LLC, Alliancebernstein L.P., Nelson Van Denburg & Campbell Wealth Management Group LLC, Victory Capital Management Inc., and Handelsbanken Fonder AB. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $13.00.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals has a market capitalization of $2.11 billion and generates $389.52 million in revenue each year. The biotechnology company earns $106.18 million in net income (profit) each year or $0.79 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals employs 232 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is

Where are Ironwood Pharmaceuticals' headquarters?

Ironwood Pharmaceuticals is headquartered at 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.